28-week treatment, 16-week follow-up , placebo controlled, double-blind,randomized study of omalizumab in patients with inadequately-controlled severe persistent allergic asthma

Trial Profile

28-week treatment, 16-week follow-up , placebo controlled, double-blind,randomized study of omalizumab in patients with inadequately-controlled severe persistent allergic asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Acronyms INNOVATE
  • Most Recent Events

    • 25 Nov 2016 Results published in Allergy.
    • 02 Nov 2016 Results comparing INNOVATE and Mensa trials presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top